116379 ⎘
Hydrolases acting on ester bonds (3.1); Phosphoric diester hydrolases (3.1.4) Sphingomyelin phosphodiesterase (3.1.4.12)
OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
#2COMPOSITIONS FOR TREATING ECTOPIC CALCIFICATION DISORDERS, AND METHODS USING SAME
#3Treatment Strategies for Pancreatic Cancer Using Recombinant Acid Sphingomyelinase
#4REAGENT COMPOSITION AND KIT
#5OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF
#6ANTIBODY SPECIFICALLY BINDING TO ASM AND USE THEREOF
#7COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB1 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING DISEASES AND DISORDERS CHARACTERIZED BY ABNORMAL CELLULAR ACCUMULATION OF SPHINGOLIPIDS SUCH AS SPHINGOMYELIN
#8ANTI-TFR:ACID SPHINGOMYELINASE FOR TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY
#9MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF
#10Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
#11OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
#12COMPOSITIONS AND METHODS FOR TREATMENT OF NIEMANN PICK TYPE A DISEASE
#13Pharmaceutical Recombinant Human Acid Sphingomyelinase Compositions and Methods
#14Methods and compositions for the treatment of steatosis-associated disorders
#15Methods and Compositions for the Treatment of Steatosis-Associated Disorders
#16Compositions for treating ectopic calcification disorders, and methods using same
#17USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR
#18DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY
#19TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS
#20OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
#21OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF
#22Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
#23Methods and compositions for the treatment of steatosis-associated disorders
#24INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES
#25Fusion proteins comprising enzyme replacement therapy enzymes
#26Methods of treating acid sphingomyelinase deficiency
#27Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
#28DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY
#29METHODS AND COMPOSITIONS FOR TUMOR RADIOSENSITIZATION
#30Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
#31RNA preparations comprising purified modified RNA for reprogramming cells
#32FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES
#33OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
#34Oligosaccharides comprising an aminooxy group and conjugates thereof
#35Fusion proteins comprising enzyme replacement therapy enzymes
#36DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY
#37INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES
#38OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
#39Methods and compositions for the treatment of steatosis-associated disorders
#40Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
#41Marker for acid sphingomyelinase disorders and uses thereof
#42RNA preparations comprising purified modified RNA for reprogramming cells
#43Method for treating a degenerative neurological disorders comprising administering ASM inhibitor
#44Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
#45TARGETED PROTEIN REPLACEMENT FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS
#46OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
#47Gene therapy for neurometabolic disorders
#48RNA preparations comprising purified modified RNA for reprogramming cells
#49Marker for acid sphingomyelinase disorders and uses thereof
#50Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
#51Composition comprising ASM inhibitor as active ingredient for preventing or treating degenerative neurological disorders
#52Intraventricular enzyme delivery for lysosomal storage diseases
#53Targeted protein replacement for the treatment of lysosomal storage disorders
#54Oligosaccharides comprising an aminooxy group and conjugates thereof
#55Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
#56Antisense oligonucleotides against neutral sphingomyelinase and neutral sphingomyelinase inhibitor GW4869 for degenerative neurological disorders
#57Compositions comprising alkaline sphingomyelinases for use as a dietetic preparation, food supplement or pharmaceutical product and methods for using them
#58Method and Composition to Increase Radiation-Induced Tumor Therapeutic Effects
#59Compositions and methods for reprogramming eukaryotic cells
#60Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
#61Oligosaccharides comprising an aminooxy group and conjugates thereof
#62Neutral Sphingomyelinase-E and Its Use
#63Oxazole compound and pharmaceutical composition
#64Targeted protein replacement for the treatment of lysosomal storage disorders
#65Intraventricular enzyme delivery for lysosomal storage diseases
#66Human alkaline sphingomyelinase and use thereof
#67Gene therapy for neurometabolic disorders
#68Sphingomyelinase compositions and use thereof
#69Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
#70Chaperone-based therapy for Niemann-Pick disease
#71Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
#72Biomarker for predicting drug resistance of bruton's tyrosine kinase inhibitors and application thereof